NO330294B1 - Nye pyrrolidin- og tiazolidinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem - Google Patents

Nye pyrrolidin- og tiazolidinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem Download PDF

Info

Publication number: NO330294B1
Authority: NO; Norway
Prior art keywords: formula; compound; group; acetyl; pyrrolidinecarbonitrile
Prior art date: 2004-05-19

Application number

NO20052414A

Other languages

English (en)

Norwegian (no)

Other versions

NO20052414L (no

NO20052414D0 (no

Inventor

Guillaume De Nanteuil

Alain Benoist

Murielle Combettes

Eliszabeth Harley

Original Assignee

Servier Lab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-05-19

Filing date

2005-05-19

Publication date

2011-03-21

2005-05-19 Application filed by Servier Lab filed Critical Servier Lab

2005-05-19 Publication of NO20052414D0 publication Critical patent/NO20052414D0/no

2005-11-21 Publication of NO20052414L publication Critical patent/NO20052414L/no

2011-03-21 Publication of NO330294B1 publication Critical patent/NO330294B1/no

Links

238000000034 method Methods 0.000 title claims description 50
238000002360 preparation method Methods 0.000 title claims description 7
239000008194 pharmaceutical composition Substances 0.000 title claims description 6
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title description 7
150000003548 thiazolidines Chemical class 0.000 title description 2
150000001875 compounds Chemical class 0.000 claims abstract description 123
150000003839 salts Chemical class 0.000 claims abstract description 29
239000002253 acid Substances 0.000 claims abstract description 25
125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 25
125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract description 5
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 5
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 5
230000003287 optical effect Effects 0.000 claims abstract description 4
125000002947 alkylene group Chemical group 0.000 claims abstract description 3
125000004429 atom Chemical group 0.000 claims abstract description 3
125000000217 alkyl group Chemical group 0.000 claims abstract 2
239000003814 drug Substances 0.000 claims abstract 2
-1 cation salts Chemical class 0.000 claims description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
125000003277 amino group Chemical group 0.000 claims description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
238000011282 treatment Methods 0.000 claims description 6
229910052799 carbon Inorganic materials 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
208000002705 Glucose Intolerance Diseases 0.000 claims description 4
206010018429 Glucose tolerance impaired Diseases 0.000 claims description 4
201000001421 hyperglycemia Diseases 0.000 claims description 4
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 4
FNTUJORREVQIJV-AWEZNQCLSA-N (2s)-4,4-difluoro-1-[2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CC(CO)(NCC(=O)N2[C@@H](CC(F)(F)C2)C#N)CCC21CCOCC2 FNTUJORREVQIJV-AWEZNQCLSA-N 0.000 claims description 3
QQZUGUHJXNTMKY-GJZGRUSLSA-N (2s,4s)-4-fluoro-1-[2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CC(CO)(NCC(=O)N2[C@@H](C[C@H](F)C2)C#N)CCC21CCOCC2 QQZUGUHJXNTMKY-GJZGRUSLSA-N 0.000 claims description 3
CQBANRWHBWWWLF-CQSZACIVSA-N (4r)-3-[2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]acetyl]-1,3-thiazolidine-4-carbonitrile Chemical compound C1CC(CO)(NCC(=O)N2[C@@H](CSC2)C#N)CCC21CCOCC2 CQBANRWHBWWWLF-CQSZACIVSA-N 0.000 claims description 3
IDBNIBONZQKSIG-NSHDSACASA-N 2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]spiro[3.3]heptane-2-carboxamide Chemical compound C1C(C(=O)N)(NCC(=O)N2[C@@H](CCC2)C#N)CC21CCC2 IDBNIBONZQKSIG-NSHDSACASA-N 0.000 claims description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
238000000926 separation method Methods 0.000 claims description 3
SMHBVUWLSCUZHN-ZDUSSCGKSA-N (2s)-1-[2-[[2-(hydroxymethyl)spiro[3.4]octan-2-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1C(CO)(NCC(=O)N2[C@@H](CCC2)C#N)CC21CCCC2 SMHBVUWLSCUZHN-ZDUSSCGKSA-N 0.000 claims description 2
BLDWRXJVHYHJNT-INIZCTEOSA-N (2s)-1-[2-[[3-(hydroxymethyl)spiro[5.5]undecan-3-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CC(CO)(NCC(=O)N2[C@@H](CCC2)C#N)CCC21CCCCC2 BLDWRXJVHYHJNT-INIZCTEOSA-N 0.000 claims description 2
LSBPCBRYNZTOJB-HNNXBMFYSA-N (2s)-1-[2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CC(CO)(NCC(=O)N2[C@@H](CCC2)C#N)CCC21CCOCC2 LSBPCBRYNZTOJB-HNNXBMFYSA-N 0.000 claims description 2
ZFFBINYAPHWTMN-OAHLLOKOSA-N (4r)-3-[2-(spiro[5.5]undecan-3-ylamino)acetyl]-1,3-thiazolidine-4-carbonitrile Chemical compound N1([C@@H](CSC1)C#N)C(=O)CNC(CC1)CCC21CCCCC2 ZFFBINYAPHWTMN-OAHLLOKOSA-N 0.000 claims description 2
239000004480 active ingredient Substances 0.000 claims description 2
150000001721 carbon Chemical group 0.000 claims description 2
231100000252 nontoxic Toxicity 0.000 claims description 2
230000003000 nontoxic effect Effects 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
238000000746 purification Methods 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims 2
229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
230000015572 biosynthetic process Effects 0.000 claims 1
239000000969 carrier Substances 0.000 claims 1
239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
238000003786 synthesis reaction Methods 0.000 claims 1
229940079593 drug Drugs 0.000 abstract 1
238000002483 medication Methods 0.000 abstract 1
125000000547 substituted alkyl group Chemical group 0.000 abstract 1
239000000047 product Substances 0.000 description 68
239000000243 solution Substances 0.000 description 20
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
KVFDZFBHBWTVID-UHFFFAOYSA-N cyclohexanecarbaldehyde Chemical compound O=CC1CCCCC1 KVFDZFBHBWTVID-UHFFFAOYSA-N 0.000 description 16
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
YCWRPKBYQZOLCD-LURJTMIESA-N (2s)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile Chemical class ClCC(=O)N1CCC[C@H]1C#N YCWRPKBYQZOLCD-LURJTMIESA-N 0.000 description 13
239000011541 reaction mixture Substances 0.000 description 13
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
238000004452 microanalysis Methods 0.000 description 7
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 6
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
FUSUHKVFWTUUBE-UHFFFAOYSA-N buten-2-one Chemical compound CC(=O)C=C FUSUHKVFWTUUBE-UHFFFAOYSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
QIRVGKYPAOQVNP-UHFFFAOYSA-N methylidenecyclobutane Chemical compound C=C1CCC1 QIRVGKYPAOQVNP-UHFFFAOYSA-N 0.000 description 6
108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 5
102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 5
238000001690 micro-dialysis Methods 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000012074 organic phase Substances 0.000 description 5
CXLGNJCMPWUZKM-UHFFFAOYSA-N oxane-4-carbaldehyde Chemical compound O=CC1CCOCC1 CXLGNJCMPWUZKM-UHFFFAOYSA-N 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
OOKHKTHERWWYQI-UHFFFAOYSA-N 3-oxaspiro[5.5]undecan-9-one Chemical compound C1CC(=O)CCC11CCOCC1 OOKHKTHERWWYQI-UHFFFAOYSA-N 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
238000004949 mass spectrometry Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 3
101800000224 Glucagon-like peptide 1 Proteins 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
102100040918 Pro-glucagon Human genes 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
229960000583 acetic acid Drugs 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000706 filtrate Substances 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
210000003734 kidney Anatomy 0.000 description 3
125000003003 spiro group Chemical group 0.000 description 3
239000000725 suspension Substances 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
229910052725 zinc Inorganic materials 0.000 description 3
239000011701 zinc Substances 0.000 description 3
KOJIQDSJFCSRSQ-ZOWNYOTGSA-N (2s)-1-[2-(7-oxaspiro[3.5]nonan-2-ylamino)acetyl]pyrrolidine-2-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CC21CCOCC2 KOJIQDSJFCSRSQ-ZOWNYOTGSA-N 0.000 description 2
XANRXJHFMPIGMV-ZOWNYOTGSA-N (2s)-1-[2-(spiro[3.4]octan-2-ylamino)acetyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CC21CCCC2 XANRXJHFMPIGMV-ZOWNYOTGSA-N 0.000 description 2
YSEZFMLSRZGYSW-UQKRIMTDSA-N (2s)-1-[2-(spiro[3.5]nonan-2-ylamino)acetyl]pyrrolidine-2-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CC21CCCCC2 YSEZFMLSRZGYSW-UQKRIMTDSA-N 0.000 description 2
MMECVPWWHWJQAC-UQKRIMTDSA-N (2s)-1-[2-(spiro[3.5]nonan-7-ylamino)acetyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.N1([C@@H](CCC1)C#N)C(=O)CNC(CC1)CCC21CCC2 MMECVPWWHWJQAC-UQKRIMTDSA-N 0.000 description 2
UFDGDTHFWPQQBI-YDALLXLXSA-N (2s)-1-[2-[[2-(hydroxymethyl)spiro[3.3]heptan-2-yl]amino]acetyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.C1C(CO)(NCC(=O)N2[C@@H](CCC2)C#N)CC21CCC2 UFDGDTHFWPQQBI-YDALLXLXSA-N 0.000 description 2
WPMZIZVPJORINX-RXMQYKEDSA-N (4r)-3-(2-chloroacetyl)-1,3-thiazolidine-4-carbonitrile Chemical compound ClCC(=O)N1CSC[C@H]1C#N WPMZIZVPJORINX-RXMQYKEDSA-N 0.000 description 2
IMADNQJYACUCLA-XFULWGLBSA-N (4r)-3-[2-(spiro[5.5]undecan-3-ylamino)acetyl]-1,3-thiazolidine-4-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1([C@@H](CSC1)C#N)C(=O)CNC(CC1)CCC21CCCCC2 IMADNQJYACUCLA-XFULWGLBSA-N 0.000 description 2
NSELYKZLLNWRED-UHFFFAOYSA-N 4-methylideneoxane Chemical compound C=C1CCOCC1 NSELYKZLLNWRED-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
208000008589 Obesity Diseases 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
239000001099 ammonium carbonate Substances 0.000 description 2
235000012501 ammonium carbonate Nutrition 0.000 description 2
TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
238000010511 deprotection reaction Methods 0.000 description 2
125000001153 fluoro group Chemical group F* 0.000 description 2
229910052736 halogen Inorganic materials 0.000 description 2
150000002367 halogens Chemical class 0.000 description 2
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
YULMNMJFAZWLLN-UHFFFAOYSA-N methylenecyclohexane Chemical compound C=C1CCCCC1 YULMNMJFAZWLLN-UHFFFAOYSA-N 0.000 description 2
WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 2
NFJPEKRRHIYYES-UHFFFAOYSA-N methylidenecyclopentane Chemical compound C=C1CCCC1 NFJPEKRRHIYYES-UHFFFAOYSA-N 0.000 description 2
235000020824 obesity Nutrition 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 2
239000000843 powder Substances 0.000 description 2
235000019260 propionic acid Nutrition 0.000 description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000003826 tablet Substances 0.000 description 2
DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 description 2
YCWRPKBYQZOLCD-ZCFIWIBFSA-N (2r)-1-(2-chloroacetyl)pyrrolidine-2-carbonitrile Chemical compound ClCC(=O)N1CCC[C@@H]1C#N YCWRPKBYQZOLCD-ZCFIWIBFSA-N 0.000 description 1
FNTUJORREVQIJV-CQSZACIVSA-N (2r)-4,4-difluoro-1-[2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CC(CO)(NCC(=O)N2[C@H](CC(F)(F)C2)C#N)CCC21CCOCC2 FNTUJORREVQIJV-CQSZACIVSA-N 0.000 description 1
ZDNSKTPOCPRHCE-MLWJPKLSSA-N (2s)-1-(2-bromopropanoyl)pyrrolidine-2-carbonitrile Chemical compound CC(Br)C(=O)N1CCC[C@H]1C#N ZDNSKTPOCPRHCE-MLWJPKLSSA-N 0.000 description 1
PBXJEAYKZGZMIE-YFKPBYRVSA-N (2s)-1-(2-chloroacetyl)-4,4-difluoropyrrolidine-2-carbonitrile Chemical compound FC1(F)C[C@@H](C#N)N(C(=O)CCl)C1 PBXJEAYKZGZMIE-YFKPBYRVSA-N 0.000 description 1
GPPVAKXAEAOISS-ZETCQYMHSA-N (2s)-1-(3-chloropropanoyl)pyrrolidine-2-carbonitrile Chemical compound ClCCC(=O)N1CCC[C@H]1C#N GPPVAKXAEAOISS-ZETCQYMHSA-N 0.000 description 1
FYFOCMSXVYVCJK-RSAXXLAASA-N (2s)-1-[2-(3-oxaspiro[5.5]undecan-9-ylamino)acetyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.N1([C@@H](CCC1)C#N)C(=O)CNC(CC1)CCC21CCOCC2 FYFOCMSXVYVCJK-RSAXXLAASA-N 0.000 description 1
GGGKJCLFIIBKHM-ZDUSSCGKSA-N (2s)-1-[2-(spiro[2.5]octan-6-ylamino)acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC(CC1)CCC21CC2 GGGKJCLFIIBKHM-ZDUSSCGKSA-N 0.000 description 1
IAZCQTFQKLQSIV-LBPRGKRZSA-N (2s)-1-[2-(spiro[3.3]heptan-2-ylamino)acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CC21CCC2 IAZCQTFQKLQSIV-LBPRGKRZSA-N 0.000 description 1
ODSJUFDNYAJLKO-YDALLXLXSA-N (2s)-1-[2-(spiro[3.3]heptan-2-ylamino)acetyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.N1([C@@H](CCC1)C#N)C(=O)CNC(C1)CC21CCC2 ODSJUFDNYAJLKO-YDALLXLXSA-N 0.000 description 1
VLMOTVPJBVRGPM-FERBBOLQSA-N (2s)-1-[2-(spiro[5.7]tridecan-3-ylamino)acetyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.N1([C@@H](CCC1)C#N)C(=O)CNC(CC1)CCC21CCCCCCC2 VLMOTVPJBVRGPM-FERBBOLQSA-N 0.000 description 1
ONEKRMDJHRWKCY-ZDUSSCGKSA-N (2s)-1-[2-[(2,2-dioxo-2$l^{6}-thiaspiro[3.5]nonan-7-yl)amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound N1([C@@H](CCC1)C#N)C(=O)CNC(CC1)CCC21CS(=O)(=O)C2 ONEKRMDJHRWKCY-ZDUSSCGKSA-N 0.000 description 1
GPJIUIFQOWQBEC-ZOWNYOTGSA-N (2s)-1-[2-[[2-(2-hydroxypropan-2-yl)spiro[3.3]heptan-2-yl]amino]acetyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.C1C(C(C)(O)C)(NCC(=O)N2[C@@H](CCC2)C#N)CC21CCC2 GPJIUIFQOWQBEC-ZOWNYOTGSA-N 0.000 description 1
CNVQGEQIJUBZGZ-ZOWNYOTGSA-N (2s)-1-[2-[[2-(hydroxymethyl)spiro[3.4]octan-2-yl]amino]acetyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.C1C(CO)(NCC(=O)N2[C@@H](CCC2)C#N)CC21CCCC2 CNVQGEQIJUBZGZ-ZOWNYOTGSA-N 0.000 description 1
POGINLSRCLMSPM-KRWDZBQOSA-N (2s)-1-[2-[[3-(hydroxymethyl)-9,9-dimethylspiro[5.5]undecan-3-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CC(C)(C)CCC21CCC(CO)(NCC(=O)N1[C@@H](CCC1)C#N)CC2 POGINLSRCLMSPM-KRWDZBQOSA-N 0.000 description 1
RWVCLPFCVMSAMZ-AWEZNQCLSA-N (2s)-1-[2-[[7-(hydroxymethyl)spiro[3.5]nonan-7-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CC(CO)(NCC(=O)N2[C@@H](CCC2)C#N)CCC21CCC2 RWVCLPFCVMSAMZ-AWEZNQCLSA-N 0.000 description 1
NCLJVPQEPRFZJR-HNNXBMFYSA-N (2s)-1-[2-[[8-(hydroxymethyl)spiro[4.5]decan-8-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CC(CO)(NCC(=O)N2[C@@H](CCC2)C#N)CCC21CCCC2 NCLJVPQEPRFZJR-HNNXBMFYSA-N 0.000 description 1
QUGCEJOLHRISTN-UFUZRDLVSA-N (2s)-1-[2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]propanoyl]pyrrolidine-2-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1([C@@H](CCC1)C#N)C(=O)C(C)NC(CC1)(CO)CCC21CCOCC2 QUGCEJOLHRISTN-UFUZRDLVSA-N 0.000 description 1
NYLIAFPDITVEFJ-LMOVPXPDSA-N (2s)-1-[3-(spiro[5.5]undecan-3-ylamino)propanoyl]pyrrolidine-2-carbonitrile;hydrochloride Chemical compound Cl.N1([C@@H](CCC1)C#N)C(=O)CCNC(CC1)CCC21CCCCC2 NYLIAFPDITVEFJ-LMOVPXPDSA-N 0.000 description 1
DMQSZIMWOFNPNR-RITPCOANSA-N (2s,4r)-1-(2-chloroacetyl)-4-fluoropyrrolidine-2-carbonitrile Chemical compound F[C@@H]1C[C@@H](C#N)N(C(=O)CCl)C1 DMQSZIMWOFNPNR-RITPCOANSA-N 0.000 description 1
UGRJLHGTEPHOCK-LIOBNPLQSA-N (2s,4r)-4-fluoro-1-[2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]acetyl]pyrrolidine-2-carbonitrile;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1CC(CO)(NCC(=O)N2[C@@H](C[C@@H](F)C2)C#N)CCC21CCOCC2 UGRJLHGTEPHOCK-LIOBNPLQSA-N 0.000 description 1
DMQSZIMWOFNPNR-WDSKDSINSA-N (2s,4s)-1-(2-chloroacetyl)-4-fluoropyrrolidine-2-carbonitrile Chemical compound F[C@H]1C[C@@H](C#N)N(C(=O)CCl)C1 DMQSZIMWOFNPNR-WDSKDSINSA-N 0.000 description 1
PBEKPIGIRCUVGJ-WDSKDSINSA-N (2s,4s)-1-(2-chloroacetyl)-4-hydroxypyrrolidine-2-carbonitrile Chemical compound O[C@H]1C[C@@H](C#N)N(C(=O)CCl)C1 PBEKPIGIRCUVGJ-WDSKDSINSA-N 0.000 description 1
BCRDJTUCYOZVJX-GJZGRUSLSA-N (2s,4s)-4-hydroxy-1-[2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CC(CO)(NCC(=O)N2[C@@H](C[C@H](O)C2)C#N)CCC21CCOCC2 BCRDJTUCYOZVJX-GJZGRUSLSA-N 0.000 description 1
MKNUBLDIUFQXPI-UHFFFAOYSA-N 1,1-dioxothiane-4-carbaldehyde Chemical compound O=CC1CCS(=O)(=O)CC1 MKNUBLDIUFQXPI-UHFFFAOYSA-N 0.000 description 1
PBXJEAYKZGZMIE-UHFFFAOYSA-N 1-(2-chloroacetyl)-4,4-difluoropyrrolidine-2-carbonitrile Chemical compound FC1(F)CC(C#N)N(C(=O)CCl)C1 PBXJEAYKZGZMIE-UHFFFAOYSA-N 0.000 description 1
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
OUKITJBUYXTGED-UHFFFAOYSA-N 1-pyrrolidin-1-yl-2-(spiro[5.5]undecan-3-ylamino)ethanone;hydrochloride Chemical compound Cl.C1CCCN1C(=O)CNC(CC1)CCC21CCCCC2 OUKITJBUYXTGED-UHFFFAOYSA-N 0.000 description 1
CEHSFHRTEXQDQE-UHFFFAOYSA-N 11-oxa-2,4-diazadispiro[4.2.5^{8}.2^{5}]pentadecane-1,3-dione Chemical compound N1C(=O)NC(=O)C11CCC2(CCOCC2)CC1 CEHSFHRTEXQDQE-UHFFFAOYSA-N 0.000 description 1
ZKKOIGGBKLNBKZ-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]spiro[3.3]heptane-2-carboxylic acid Chemical compound C1C(NC(=O)OC(C)(C)C)(C(O)=O)CC11CCC1 ZKKOIGGBKLNBKZ-UHFFFAOYSA-N 0.000 description 1
LVOPAPRIWULVGA-UHFFFAOYSA-N 2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]-1-(3,3,4,4-tetrafluoropyrrolidin-1-yl)ethanone Chemical compound C1CC(CO)(NCC(=O)N2CC(F)(F)C(F)(F)C2)CCC21CCOCC2 LVOPAPRIWULVGA-UHFFFAOYSA-N 0.000 description 1
RXRIZSZHHUMWJM-UHFFFAOYSA-N 2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]-1-pyrrolidin-1-ylethanone Chemical compound C1CC(CO)(NCC(=O)N2CCCC2)CCC21CCOCC2 RXRIZSZHHUMWJM-UHFFFAOYSA-N 0.000 description 1
JGPDMXRVYWPLNA-UHFFFAOYSA-N 2-aminospiro[3.3]heptane-2-carboxylic acid Chemical compound C1C(N)(C(O)=O)CC11CCC1 JGPDMXRVYWPLNA-UHFFFAOYSA-N 0.000 description 1
UGLQLLAYBADIEX-YFKPBYRVSA-N 2-chloro-1-[(3s)-3-fluoropyrrolidin-1-yl]ethanone Chemical compound F[C@H]1CCN(C(=O)CCl)C1 UGLQLLAYBADIEX-YFKPBYRVSA-N 0.000 description 1
AAOSLLBWWRKJIR-UHFFFAOYSA-N 2-chloro-1-pyrrolidin-1-ylethanone Chemical compound ClCC(=O)N1CCCC1 AAOSLLBWWRKJIR-UHFFFAOYSA-N 0.000 description 1
ZHEGZTCKKDJSHF-UHFFFAOYSA-N 3,3-dichlorospiro[3.3]heptan-2-one Chemical compound ClC1(Cl)C(=O)CC11CCC1 ZHEGZTCKKDJSHF-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
SWFLJBVLNHOYOI-UHFFFAOYSA-N 3-oxaspiro[5.5]undec-10-en-9-one Chemical compound C1=CC(=O)CCC11CCOCC1 SWFLJBVLNHOYOI-UHFFFAOYSA-N 0.000 description 1
FNTUJORREVQIJV-UHFFFAOYSA-N 4,4-difluoro-1-[2-[[9-(hydroxymethyl)-3-oxaspiro[5.5]undecan-9-yl]amino]acetyl]pyrrolidine-2-carbonitrile Chemical compound C1CC(CO)(NCC(=O)N2C(CC(F)(F)C2)C#N)CCC21CCOCC2 FNTUJORREVQIJV-UHFFFAOYSA-N 0.000 description 1
AAEIBLQPASHLSV-UHFFFAOYSA-N 4,4-dimethylcyclohexane-1-carbaldehyde Chemical compound CC1(C)CCC(C=O)CC1 AAEIBLQPASHLSV-UHFFFAOYSA-N 0.000 description 1
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
241000255969 Pieris brassicae Species 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
235000008206 alpha-amino acids Nutrition 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
239000000908 ammonium hydroxide Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004296 chiral HPLC Methods 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
UGBFRCHGZFHSBC-UHFFFAOYSA-N cycloheptanecarbaldehyde Chemical compound O=CC1CCCCCC1 UGBFRCHGZFHSBC-UHFFFAOYSA-N 0.000 description 1
IGGUWVNICWZJQU-UHFFFAOYSA-N cyclooctanecarbaldehyde Chemical compound O=CC1CCCCCCC1 IGGUWVNICWZJQU-UHFFFAOYSA-N 0.000 description 1
VELDYOPRLMJFIK-UHFFFAOYSA-N cyclopentanecarbaldehyde Chemical compound O=CC1CCCC1 VELDYOPRLMJFIK-UHFFFAOYSA-N 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
239000008298 dragée Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
BJXBCCBWZNBFAP-UHFFFAOYSA-N ethyl 3-[1-(3-ethoxy-3-oxopropyl)cyclobutyl]propanoate Chemical compound CCOC(=O)CCC1(CCC(=O)OCC)CCC1 BJXBCCBWZNBFAP-UHFFFAOYSA-N 0.000 description 1
IFLIONPIQRLKTJ-UHFFFAOYSA-N ethyl 7-oxospiro[3.5]nonane-8-carboxylate Chemical compound C1CC(=O)C(C(=O)OCC)CC11CCC1 IFLIONPIQRLKTJ-UHFFFAOYSA-N 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
108010077515 glycylproline Proteins 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
FSIVXDSCKCVROC-UHFFFAOYSA-N methyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]spiro[3.3]heptane-2-carboxylate Chemical compound C1C(C(=O)OC)(NC(=O)OC(C)(C)C)CC11CCC1 FSIVXDSCKCVROC-UHFFFAOYSA-N 0.000 description 1
GASFARBVOCDRLO-UHFFFAOYSA-N methyl 2-aminospiro[3.3]heptane-2-carboxylate Chemical compound C1C(C(=O)OC)(N)CC11CCC1 GASFARBVOCDRLO-UHFFFAOYSA-N 0.000 description 1
RPGYLEXNOYTVKM-UHFFFAOYSA-N n-spiro[5.5]undecan-3-ylidenehydroxylamine Chemical compound C1CC(=NO)CCC11CCCCC1 RPGYLEXNOYTVKM-UHFFFAOYSA-N 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000007170 pathology Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007787 solid Substances 0.000 description 1
PXIGSUWVCSOFMF-UHFFFAOYSA-N spiro[2.5]octan-6-one Chemical compound C1CC(=O)CCC11CC1 PXIGSUWVCSOFMF-UHFFFAOYSA-N 0.000 description 1
AOAIWGRQECAIKB-UHFFFAOYSA-N spiro[3.3]heptan-2-one Chemical compound C1C(=O)CC11CCC1 AOAIWGRQECAIKB-UHFFFAOYSA-N 0.000 description 1
FGUMOUPJTIVALZ-UHFFFAOYSA-N spiro[3.4]octan-2-one Chemical compound C1C(=O)CC21CCCC2 FGUMOUPJTIVALZ-UHFFFAOYSA-N 0.000 description 1
NRNKZKFTQBNHBT-UHFFFAOYSA-N spiro[3.5]nonan-2-one Chemical compound C1C(=O)CC21CCCCC2 NRNKZKFTQBNHBT-UHFFFAOYSA-N 0.000 description 1
YNMVUESBVUUFDF-UHFFFAOYSA-N spiro[3.5]nonan-7-one Chemical compound C1CC(=O)CCC11CCC1 YNMVUESBVUUFDF-UHFFFAOYSA-N 0.000 description 1
BAERJJQGHJOXHR-UHFFFAOYSA-N spiro[5.5]undecan-3-amine Chemical compound C1CC(N)CCC11CCCCC1 BAERJJQGHJOXHR-UHFFFAOYSA-N 0.000 description 1
QIPAUQVWJAXYOQ-UHFFFAOYSA-N spiro[5.5]undecan-3-one Chemical compound C1CC(=O)CCC11CCCCC1 QIPAUQVWJAXYOQ-UHFFFAOYSA-N 0.000 description 1
IMXNDGKDOMFUFR-UHFFFAOYSA-N spiro[5.5]undecane-3-carbaldehyde Chemical compound C1CC(C=O)CCC11CCCCC1 IMXNDGKDOMFUFR-UHFFFAOYSA-N 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
KIRHQHDBUWJHPP-UHFFFAOYSA-N tert-butyl n-(2-carbamoylspiro[3.3]heptan-2-yl)carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)(C(N)=O)CC11CCC1 KIRHQHDBUWJHPP-UHFFFAOYSA-N 0.000 description 1
GQJYLUCLOMGOSP-UHFFFAOYSA-N tert-butyl n-[2-(2-hydroxypropan-2-yl)spiro[3.3]heptan-2-yl]carbamate Chemical compound C1C(NC(=O)OC(C)(C)C)(C(C)(C)O)CC11CCC1 GQJYLUCLOMGOSP-UHFFFAOYSA-N 0.000 description 1
239000000341 volatile oil Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Diabetes (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pyrrole Compounds (AREA)
Pyrane Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20052414A 2004-05-19 2005-05-19 Nye pyrrolidin- og tiazolidinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem NO330294B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0405454A FR2870538B1 (fr)	2004-05-19	2004-05-19	Nouveaux derives de pyrrolidines et de thiazolidines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (3)

Publication Number	Publication Date
NO20052414D0 NO20052414D0 (no)	2005-05-19
NO20052414L NO20052414L (no)	2005-11-21
NO330294B1 true NO330294B1 (no)	2011-03-21

Family

ID=34942306

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20052414A NO330294B1 (no)	2004-05-19	2005-05-19	Nye pyrrolidin- og tiazolidinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem

Country Status (28)

Country	Link
US (1)	US7439263B2 (pl)
EP (1)	EP1598350B1 (pl)
JP (1)	JP4335171B2 (pl)
KR (1)	KR100747967B1 (pl)
CN (1)	CN100381438C (pl)
AR (1)	AR049278A1 (pl)
AT (1)	ATE366731T1 (pl)
AU (1)	AU2005202180B2 (pl)
BR (1)	BRPI0501769A (pl)
CA (1)	CA2506491C (pl)
CY (1)	CY1106878T1 (pl)
DE (1)	DE602005001576T2 (pl)
DK (1)	DK1598350T3 (pl)
EA (1)	EA009292B1 (pl)
ES (1)	ES2290864T3 (pl)
FR (1)	FR2870538B1 (pl)
GE (1)	GEP20074103B (pl)
HR (1)	HRP20070376T3 (pl)
MX (1)	MXPA05005256A (pl)
MY (1)	MY139481A (pl)
NO (1)	NO330294B1 (pl)
NZ (1)	NZ540108A (pl)
PL (1)	PL1598350T3 (pl)
PT (1)	PT1598350E (pl)
RS (1)	RS50526B (pl)
SG (1)	SG117551A1 (pl)
SI (1)	SI1598350T1 (pl)
ZA (1)	ZA200504050B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2020413A1 (de)	2007-08-02	2009-02-04	Bayer CropScience AG	Oxaspirocyclische-spiro-substituierte Tetram- und Tetronsäure-Derivate
US8338450B2 (en) *	2007-09-21	2012-12-25	Lupin Limited	Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
US8304411B2 (en) *	2008-01-23	2012-11-06	Jiangsu Hansoh Pharmaceutical Co., Ltd.	Dicycloazaalkane derivates, preparation processes and medical uses thereof
US8748457B2 (en)	2009-06-18	2014-06-10	Lupin Limited	2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors
US8440710B2 (en) *	2009-10-15	2013-05-14	Hoffmann-La Roche Inc.	HSL inhibitors useful in the treatment of diabetes
US9567300B2 (en)	2012-06-25	2017-02-14	Sunshine Lake Pharma Co., Ltd.	Hexahydropentaleno derivatives, preparation method and use in medicine thereof
KR102449196B1 (ko)	2016-01-15	2022-09-29	삼성전자주식회사	비휘발성 메모리 장치 및 비휘발성 메모리 장치의 프로그램 방법

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0618957B2 (ja) *	1988-01-26	1994-03-16	日本合成化学工業株式会社	成形物の製造方法
CA2046801C (en) *	1990-08-07	2002-02-26	Peter D. Davis	Substituted pyrroles
DE4222459C2 (de) *	1992-07-08	1995-09-14	Sigma Tau Ind Farmaceuti	3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten
ATE208779T1 (de) *	1993-07-02	2001-11-15	Bayer Ag	Substituierte spiroheterocyclische 1h-3-aryl- pyrrolidin-2,4-dion-derivate, verfahren zu deren herstellung und deren verwendung als schädlingsbekämpfungsmittel
TW492957B (en) *	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
US6110949A (en) *	1999-06-24	2000-08-29	Novartis Ag	N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
TW583185B (en) *	2000-06-13	2004-04-11	Novartis Ag	N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same
DK1308439T3 (da) *	2000-08-10	2009-01-12	Mitsubishi Tanabe Pharma Corp	Prolinderivater og anvendelse af disse som lægemidler
AU2001288114B2 (en) *	2000-09-25	2006-04-27	Toray Industries, Inc.	Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
FR2824825B1 (fr) *	2001-05-15	2005-05-06	Servier Lab	Nouveaux derives d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002360732A1 (en) *	2001-12-26	2003-07-24	Guilford Pharmaceuticals	Change inhibitors of dipeptidyl peptidase iv
HUP0200849A2 (hu) *	2002-03-06	2004-08-30	Sanofi-Synthelabo	N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
KR20040105853A (ko) *	2002-04-08	2004-12-16	토렌트 파마슈티칼스 리미티드	티아졸리딘-4-카르보니트릴 및 유사체와디펩티딜-펩티다아제 억제제로서의 용도
TW200404796A (en) *	2002-08-19	2004-04-01	Ono Pharmaceutical Co	Nitrogen-containing compound
US7262207B2 (en) *	2002-09-19	2007-08-28	Abbott Laboratories	Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
MXPA05004890A (es) *	2002-11-07	2005-07-22	Merck & Co Inc	Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevencion de diabetes.

2004
- 2004-05-19 FR FR0405454A patent/FR2870538B1/fr not_active Expired - Fee Related
2005
- 2005-05-04 SG SG200502766A patent/SG117551A1/en unknown
- 2005-05-05 CA CA002506491A patent/CA2506491C/fr not_active Expired - Fee Related
- 2005-05-17 MX MXPA05005256A patent/MXPA05005256A/es active IP Right Grant
- 2005-05-18 AR ARP050102045A patent/AR049278A1/es unknown
- 2005-05-18 EP EP05291066A patent/EP1598350B1/fr not_active Expired - Lifetime
- 2005-05-18 PT PT05291066T patent/PT1598350E/pt unknown
- 2005-05-18 AT AT05291066T patent/ATE366731T1/de active
- 2005-05-18 DE DE602005001576T patent/DE602005001576T2/de not_active Expired - Lifetime
- 2005-05-18 MY MYPI20052248A patent/MY139481A/en unknown
- 2005-05-18 US US11/131,510 patent/US7439263B2/en not_active Expired - Fee Related
- 2005-05-18 EA EA200500683A patent/EA009292B1/ru not_active IP Right Cessation
- 2005-05-18 RS RSP-2007/0392A patent/RS50526B/sr unknown
- 2005-05-18 NZ NZ540108A patent/NZ540108A/en unknown
- 2005-05-18 ES ES05291066T patent/ES2290864T3/es not_active Expired - Lifetime
- 2005-05-18 SI SI200530030T patent/SI1598350T1/sl unknown
- 2005-05-18 GE GEAP20058802A patent/GEP20074103B/en unknown
- 2005-05-18 DK DK05291066T patent/DK1598350T3/da active
- 2005-05-18 KR KR1020050041742A patent/KR100747967B1/ko not_active Expired - Fee Related
- 2005-05-18 PL PL05291066T patent/PL1598350T3/pl unknown
- 2005-05-19 ZA ZA200504050A patent/ZA200504050B/en unknown
- 2005-05-19 CN CNB200510087845XA patent/CN100381438C/zh not_active Expired - Fee Related
- 2005-05-19 AU AU2005202180A patent/AU2005202180B2/en not_active Ceased
- 2005-05-19 JP JP2005146186A patent/JP4335171B2/ja not_active Expired - Fee Related
- 2005-05-19 BR BR0501769-6A patent/BRPI0501769A/pt not_active IP Right Cessation
- 2005-05-19 NO NO20052414A patent/NO330294B1/no not_active IP Right Cessation
2007
- 2007-09-03 HR HR20070376T patent/HRP20070376T3/xx unknown
- 2007-09-19 CY CY20071101205T patent/CY1106878T1/el unknown

Also Published As

Publication number	Publication date
CN1721417A (zh)	2006-01-18
FR2870538B1 (fr)	2006-07-14
DK1598350T3 (da)	2007-11-12
JP2005350456A (ja)	2005-12-22
CA2506491A1 (fr)	2005-11-19
ZA200504050B (en)	2006-07-26
US20050261501A1 (en)	2005-11-24
JP4335171B2 (ja)	2009-09-30
DE602005001576T2 (de)	2008-04-17
GEP20074103B (en)	2007-05-10
EA009292B1 (ru)	2007-12-28
CY1106878T1 (el)	2012-09-26
BRPI0501769A (pt)	2006-01-10
AU2005202180A1 (en)	2005-12-08
ES2290864T3 (es)	2008-02-16
NO20052414L (no)	2005-11-21
AR049278A1 (es)	2006-07-12
CN100381438C (zh)	2008-04-16
US7439263B2 (en)	2008-10-21
PL1598350T3 (pl)	2007-10-31
EP1598350B1 (fr)	2007-07-11
HRP20070376T3 (en)	2007-12-31
DE602005001576D1 (de)	2007-08-23
KR20060048007A (ko)	2006-05-18
AU2005202180B2 (en)	2010-10-28
KR100747967B1 (ko)	2007-08-08
FR2870538A1 (fr)	2005-11-25
MXPA05005256A (es)	2005-11-24
PT1598350E (pt)	2007-10-04
CA2506491C (fr)	2009-09-01
EP1598350A1 (fr)	2005-11-23
MY139481A (en)	2009-10-30
HK1086259A1 (zh)	2006-09-15
EA200500683A1 (ru)	2005-12-29
RS50526B (sr)	2010-05-07
SI1598350T1 (sl)	2007-10-31
ATE366731T1 (de)	2007-08-15
SG117551A1 (en)	2005-12-29
NO20052414D0 (no)	2005-05-19
NZ540108A (en)	2006-04-28

Legal Events

Date	Code	Title	Description
2012-12-27	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
RS52397B (sr)	2013-02-28	Derivati pirido /2,1-a/izohinolina kao dpp-iv inhibitori
US7399779B2 (en)	2008-07-15	3,6-disubstituted azabicyclo [3.1.0] hexane derivatives useful as muscarinic receptor antagonists
AU2002344820B2 (en)	2006-12-14	Dipeptidyl peptidase inhibitors for the treatment of diabetes
US8178575B2 (en)	2012-05-15	Derivatives of azabicyclo octane, the method of making them and the uses thereof as inhibitors of dipeptidyl peptidase IV
US20210023049A1 (en)	2021-01-28	Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders
WO2005033099A2 (en)	2005-04-14	Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof
MXPA04008278A (es)	2005-09-20	Inhibidores de dipeptidil peptidasa iv a base de glutaminil.
NZ511935A (en)	2003-11-28	N-substituted 2-cyanopyrrolidines
Cardona et al.	2000	Polyhydroxypyrrolidine glycosidase inhibitors related to (+)-lentiginosine
EP1615634B1 (en)	2007-05-16	Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP4335171B2 (ja)	2009-09-30	新規なピロリジン及びチアゾリジン化合物、その製造方法及びそれを含有する医薬組成物
WO2006090244A1 (en)	2006-08-31	New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them
HK1086259B (en)	2008-11-28	New pyrrolidine and thiazolidine compounds, a process for their preparation and pharmaceutical compositions containing them
KR20100057035A (ko)	2010-05-28	(ｓ)-2-((4-벤조푸라닐)카르보닐아미노메틸)-1-((4-(2-메틸-5-(4-플루오로페닐))티아졸릴)카르보닐)피페리딘의 다형체 형태
FR2552087A1 (fr)	1985-03-22	Nouveaux composes spiranniques acylmercapto-alcanoyliques et mercapto-alcanoyliques utiles notamment comme medicaments antihypertenseurs
HK1079783B (en)	2009-07-24	3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists